The National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) has awarded a $274,991 Project Grant to Saber Therapeutics, Inc. to develop a new approach for delivering cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The goal is to create natural killer (NK) cells engineered with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting engineered NK cells will be tested for their ability to selectively kill AML cancer cells. This project aims to lay the foundational proof-of-concept for a novel cancer therapy that could potentially address the limitations of existing treatments like chimeric antigen receptor T-cells (CAR-Ts). If successful, the research could lead to the development of a new generation of anti-cancer medicines. The award period is from September 1, 2024 to August 31, 2025.
Generated 3/18/25, 4:39 AM